# Noetik

Source: https://onco.cc/companies/noetik/  
OnCo record `noetik` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Noetik builds artificial intelligence models of tumours from huge sets of tissue images and molecular data, to predict which patients will respond to a cancer drug and to find new targets.

## Summary

Noetik, founded in 2023 in South San Francisco, is an AI-native biotechnology company that has assembled one of the largest multimodal tumour datasets (spatial transcriptomics, proteomics, histology and genomics from patient samples) plus its Perturb-map in vivo functional genomics platform. On these it trains foundation models of the tumour microenvironment, including OCTO-VirtualCell, Celleporter and TARIO-2, which identifies likely responders to the checkpoint combination botensilimab plus balstilimab from routine pathology images (June 2026, following a 2025 biomarker collaboration with Agenus). Applications span trial enrichment, repositioning of clinical-stage drugs and novel target discovery. In January 2026 GSK licensed Noetik's foundation models in an anchor partnership reported at USD 50 million. Noetik raised a USD 14 million seed led by DCVC (2023) and a USD 40 million Series A (2024).

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: South San Francisco, CA
- Type: ai-software
- Website: https://www.noetik.ai

## Notes

- Series A lead investor not named on fetched pages (Business Wire release blocked). Investor names other than DCVC come from logos on the company homepage.

## Sources

- Official website: https://www.noetik.ai
- News (Series A, GSK partnership): https://www.noetik.ai/news
- DCVC leads USD 14 million seed: https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Pathology & radiology foundation models](https://onco.cc/technologies/pathology-foundation-model/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/)
- companies: [DCVC](https://onco.cc/companies/dcvc/), [Khosla Ventures](https://onco.cc/companies/khosla-ventures/), [Polaris Partners](https://onco.cc/companies/polaris-partners/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/)
- terms: [Virtual cell models and in-silico perturbation screens](https://onco.cc/terms/virtual-cell-models/)

---
JSON: https://onco.cc/api/v1/entities/noetik.json